Apollo Endosurgery, Inc. (APEN)

1 member of Congress has disclosed 8 trades in Apollo Endosurgery, Inc. (APEN) via STOCK Act filings. The most recent disclosure was a purchase by Tom Malinowski on 30 October 2020. Aggregate disclosed activity totals roughly $40K in purchases and $24K in sales (midpoint estimates from bracketed disclosure amounts).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Price data is not available for APEN
This ticker may have been delisted, renamed, or is not publicly quoted, so no live price, statistics or chart can be shown. The congressional trades disclosed for it are listed below.

Congressional Trading Activity for APEN

5 transactions
Compliance: 38%
Tom Malinowski30 Oct 202026 Aug 2021PurchaseStock$1,001 - $15,000N/A
Tom Malinowski30 Oct 202026 Aug 2021PurchaseStock$1,001 - $15,000N/A
Tom Malinowski2 Oct 20205 Mar 2021PurchaseStock$1,001 - $15,000N/A
Tom Malinowski2 Oct 202030 Jul 2021PurchaseStock$1,001 - $15,000N/A
Tom Malinowski2 Oct 202026 Aug 2021PurchaseStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Stock Overview

Market Data

Market Cap

$579.72M

Volume

1.64M

Beta

2.32

P/E Ratio

-9.43

Fundamentals

EPS

$-1.06

Div. Yield

-

Open

$9.93

Day Range

$9.92 – $10.00

Company Information

Sector
Healthcare
Industry
Medical - Devices
Exchange
NASDAQ · USD
Country
US
CEO
Charles S. McKhann
IPO Date
2005-04-21
Website
www.endura.com

Apollo Endosurgery, Inc. is a medical technology firm specializing in the creation, development, and commercialization of advanced medical instruments. Among its products are the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which empower...

Earnings

Recent Quarters

Q4 202230 Mar
EPS$0.23
Beat 209.5%
Q3 20221 Nov
EPS$-0.28
Miss 21.7%
Q2 20222 Aug
EPS$-0.26
Miss 18.2%
Q1 20223 May
EPS$-0.21
Miss 5.0%
Q4 202122 Feb
EPS$-0.27
Miss 42.1%
Q3 20211 Nov
EPS$-0.23
Beat 17.9%
Q2 20213 Aug
EPS$-0.11
Beat 45.0%
Q1 20214 May
EPS$-0.17
Beat 22.7%
Q4 202025 Feb
EPS$-0.14
Beat 44.0%
Q3 20205 Nov
EPS$-0.11
Beat 47.6%
Q2 20204 Aug
EPS$-0.30
Beat 9.1%
Q1 20204 May
EPS$-0.49
Beat 0.0%
Q4 201926 Mar
EPS$-0.34
Beat 10.5%
Q3 201930 Oct
EPS$-0.40
Beat 4.8%
Q2 201923 Jul
EPS$-0.40
Miss 5.3%
Q1 20192 May
EPS$-0.13
Beat 63.9%
Q4 201818 Mar
EPS$-0.48
Miss 29.7%
Q3 20188 Nov
EPS$-0.45
Miss 28.6%
Q2 20188 Aug
EPS$-0.53
Miss 20.4%
Q1 20183 May
EPS$-0.47
Miss 17.5%
Q4 20171 Mar
EPS$-0.42
Miss 23.5%
Q3 201726 Oct
EPS$-0.32
Beat 20.0%
Q2 20171 Aug
EPS$-0.64
Miss 166.7%
Q1 20174 May
EPS$-0.77
Q4 20168 Mar
EPS$-58.35
Q3 201610 Nov
EPS$-8.49
Q2 20169 Aug
EPS$-6.12
Q1 201610 May
EPS$-4.47
Q4 201522 Mar
EPS$-5.38
Q3 201512 Nov
EPS$-5.83
Q2 201511 Aug
EPS$-9.91
Q1 20158 May
EPS$-10.83
Q4 201422 Mar
EPS$-26.18
Beat 0.0%
Q3 201412 Nov
EPS$-15.40
Beat 39.4%
Q2 20148 Aug
EPS$-17.71
Miss 56.9%
Q1 20149 May
EPS$-17.71
Miss 100.1%
Q4 201318 Mar
EPS$-8.47
Miss 10.0%
Q3 20138 Nov
EPS$-14.63
Miss 3.6%
Q2 201314 Aug
EPS$-10.78
Beat 46.1%
Q1 20137 May
EPS$-8.47
Beat 15.4%
Q4 201215 Mar
EPS$-12.32
Miss 10.4%
Q3 20129 Nov
EPS$-7.70
Miss 11.1%
Q2 201213 Aug
EPS$-4.53
Beat 57.9%
Q1 201214 May
EPS$5.39
Beat 150.0%
Q4 201116 Mar
EPS$-32.34
Miss 100.0%
Q3 201114 Nov
EPS$9.66
Q2 201112 Aug
EPS$11.27
Beat 204.6%
Q1 201110 May
EPS$-14.17
Q4 201023 Mar
EPS$-8.52
Q3 20109 Nov
EPS$-28.99
Miss 437.9%
Q2 201012 Aug
EPS$-10.78
Q1 201012 May
EPS$5.39
Q4 200930 Mar
EPS$-0.41
Q3 200912 Nov
EPS$69.52
Q2 200912 Aug
EPS$-38.87
Miss 621.1%
Q1 200915 May
EPS$5.45
Q4 200825 Mar
EPS$-17.19
Q3 200813 Nov
EPS$-23.73
Q2 200814 Aug
EPS$-28.96
Q1 200812 May
EPS$-60.60
Q4 200720 Mar
EPS$-50.78
Q3 200713 Nov
EPS$-55.16
Q2 200713 Aug
EPS$-47.21
Beat 2.7%
Q1 200714 May
EPS$-59.41
Q1 200716 Apr
EPS$-33.61
Q3 200613 Nov
EPS$-27.93
Q2 200611 Aug
EPS$-32.13
Q1 200612 May
EPS$-29.71
Q4 200516 Mar
EPS$-62.79
Q3 200528 Oct
EPS$-0.07
Q2 200519 Aug
EPS$-0.09
Q1 200512 May
EPS$-0.18

5 politicians traded within 30 days

No dividend data available for this stock.

Stock Splits

Split History

30 Dec 2016Reverse Split
Ratio2:11
13 Jun 2016Reverse Split
Ratio1:14
9 Oct 2012Reverse Split
Ratio1:7

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about APEN

Which members of Congress have traded APEN?
1 member of Congress has disclosed 8 trade in Apollo Endosurgery, Inc. (APEN) under the STOCK Act: Tom Malinowski.
When was APEN most recently disclosed by Congress?
The most recent APEN disclosure was a purchase by Tom Malinowski on 30 October 2020.
What is the total disclosed congressional trading volume for APEN?
Members of Congress have disclosed approximately $40K in APEN purchases and $24K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in APEN?
This APEN page updates as soon as new STOCK Act disclosures are filed for Apollo Endosurgery, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.